Global Chronic Plaque Psoriasis API Manufacturers, Marketed and Phase III Drugs Landscape, 2018-2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic
Plaque Psoriasis – Global API Manufacturers, Marketed and Phase III
Drugs Landscape, 2018”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Chronic Plaque Psoriasis – Global API Manufacturers, Marketed and Phase
III Drugs Landscape, 2018′ report provides comprehensive insights about
marketed and Phase III products for Chronic Plaque Psoriasis . The
report includes information of marketed products including their product
description, patent details, forecasted sales till 2020 & API
manufacturer details by country.

Coverage of API manufacturers for Chronic Plaque Psoriasis marketed
products spanning across United States, Europe, China and India. The
manufacturers’ details include manufacturers’ name along with their
location.

This report provides a comprehensive understanding of the emerging Phase
III therapies for Chronic Plaque Psoriasis which can turn out to be
future prospective competitors for the marketed products. It will also
put light on the current market trends. Their forecasted global sales
are also provided till 2020.

Key Topics Covered:

1. Report Introduction

2. Chronic Plaque Psoriasis: Overview

  • Risk Factors
  • Causes
  • Symptoms
  • Pathophysiology
  • Prognosis
  • Diagnosis
  • Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

4.1. Company name

  • Product Description
  • Route of Synthesis
  • Mechanism of Action
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Adverse Reactions
  • Clinical Trials
  • Regulatory Milestones
  • Product Development Activities

4.1.1 Product Details

  • United States
  • Europe

4.1.2 Global Sales Assessment

  • Historical Global Sales
  • Forecasted Global Sales

4.1.3 Patent Details

Other marketed products in the detailed report

5. Emerging Therapies (Phase III)

5.1 Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

5.1.1 Forecasted Global Sales

Other Phase III profiles in the detailed report

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/n8fkzx/global_chronic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs
, Psoriasis
Drugs